Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2021

Open Access 01-12-2021 | Phenylketonuria | Research

Patient’s thoughts and expectations about centres of expertise for PKU

Authors: A. M. J. van Wegberg, A. MacDonald, D. Abeln, T. S. Hagedorn, E. Lange, F. Trefz, D. van Vliet, F. J. van Spronsen

Published in: Orphanet Journal of Rare Diseases | Issue 1/2021

Login to get access

Abstract

Background

In the Netherlands (NL) the government assigned 2 hospitals as centres of expertise (CE) for Phenylketonuria (PKU), while in the United Kingdom (UK) and Germany no centres are assigned specifically as PKU CE’s.

Methods

To identify expectations of patients/caregivers with PKU of CEs, a web-based survey was distributed through the national Phenylketonuria societies of Germany, NL and UK.

Results

In total, 105 responded (43 patients, 56 parents, 4 grandparents, 2 other) of whom 59 were from NL, 33 from UK and 13 from Germany. All participants (n = 105) agreed that patients and/or practitioners would benefit from CEs. The frequency patients would want to visit a CE, when not treated in a CE (n = 83) varied: every hospital visit (24%, n = 20), annual or bi-annual (45%, n = 37), at defined patient ages (6%, n = 5), one visit only (22%, n = 18), or never (4%, n = 3). Distance was reported as a major barrier (42%, n = 35). 78% (n = 65) expected CE physicians and dieticians to have a higher level of knowledge than in non-CE centres. For participants already treated in a CE (n = 68), 66% requested a more extensive annual or bi-annual review. In general, psychology review and neuropsychologist assessment were identified as necessary by approximately half of the 105 participants. In addition, 66% (n = 68) expected a strong collaboration with patient associations.

Conclusion

In this small study, most participants expected that assigning CEs will change the structure of and delivery of Phenylketonuria care.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference EUCERD, Recommendations on quality criteria for centres of expertise for rare diseases in member states 2011. www.eucerd.eu. EUCERD, Recommendations on quality criteria for centres of expertise for rare diseases in member states 2011. www.​eucerd.​eu.
4.
go back to reference Taruscio D, et al. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. EUCERD Recomm Blood Transfus. 2014;12(Suppl 3):s621–5. Taruscio D, et al. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. EUCERD Recomm Blood Transfus. 2014;12(Suppl 3):s621–5.
5.
go back to reference Hannemann-Weber H, Kessel M, Schultz C. Research performance of centers of expertise for rare diseases—the influence of network integration, internal resource access and operational experience. Health Policy. 2012;105(2–3):138–45.PubMedCrossRef Hannemann-Weber H, Kessel M, Schultz C. Research performance of centers of expertise for rare diseases—the influence of network integration, internal resource access and operational experience. Health Policy. 2012;105(2–3):138–45.PubMedCrossRef
6.
go back to reference Plockinger U, Ziagaki A. The German National Action League for people with rare diseases: translating the three tiers center system into active co-operation, a one center experience. Orphanet J Rare Dis. 2019;14(1):158.PubMedPubMedCentralCrossRef Plockinger U, Ziagaki A. The German National Action League for people with rare diseases: translating the three tiers center system into active co-operation, a one center experience. Orphanet J Rare Dis. 2019;14(1):158.PubMedPubMedCentralCrossRef
7.
go back to reference Camfield CS, et al. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr. 2004;145(1):53–7.PubMedCrossRef Camfield CS, et al. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr. 2004;145(1):53–7.PubMedCrossRef
8.
go back to reference DeWard SJ, et al. Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience. J Genet Couns. 2014;23(1):20–8.PubMedCrossRef DeWard SJ, et al. Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience. J Genet Couns. 2014;23(1):20–8.PubMedCrossRef
9.
go back to reference Donaghy E, et al. Acceptability, benefits, and challenges of video consulting: a qualitative study in primary care. Br J Gen Pract. 2019;69(686):e586–94.PubMedPubMedCentralCrossRef Donaghy E, et al. Acceptability, benefits, and challenges of video consulting: a qualitative study in primary care. Br J Gen Pract. 2019;69(686):e586–94.PubMedPubMedCentralCrossRef
10.
go back to reference Honarmand K, et al. Feasibility of a web-based neurocognitive battery for assessing cognitive function in critical illness survivors. PLoS ONE. 2019;14(4):e0215203.PubMedPubMedCentralCrossRef Honarmand K, et al. Feasibility of a web-based neurocognitive battery for assessing cognitive function in critical illness survivors. PLoS ONE. 2019;14(4):e0215203.PubMedPubMedCentralCrossRef
11.
go back to reference Silverstein SM, et al. Development and validation of a World-Wide-Web-based neurocognitive assessment battery: WebNeuro. Behav Res Methods. 2007;39(4):940–9.PubMedCrossRef Silverstein SM, et al. Development and validation of a World-Wide-Web-based neurocognitive assessment battery: WebNeuro. Behav Res Methods. 2007;39(4):940–9.PubMedCrossRef
12.
go back to reference Backx, R., et al. Bringing Home Cognitive Assessment: Initial Validation of Unsupervised Web-based Cognitive Testing on the Cambridge Neuropsychological Test Automated Battery (CANTAB) using a within-subjects counterbalanced design. Journal of Medical Internet Research 2020. Backx, R., et al. Bringing Home Cognitive Assessment: Initial Validation of Unsupervised Web-based Cognitive Testing on the Cambridge Neuropsychological Test Automated Battery (CANTAB) using a within-subjects counterbalanced design. Journal of Medical Internet Research 2020.
13.
go back to reference van Spronsen FJ, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.PubMedCrossRef van Spronsen FJ, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.PubMedCrossRef
16.
17.
go back to reference Jahja R, et al. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr. 2014;164(4):895–9 e2.PubMedCrossRef Jahja R, et al. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr. 2014;164(4):895–9 e2.PubMedCrossRef
18.
go back to reference de Groot MJ, et al. Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis. J Cereb Blood Flow Metab. 2015;35(2):200–5.PubMedCrossRef de Groot MJ, et al. Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis. J Cereb Blood Flow Metab. 2015;35(2):200–5.PubMedCrossRef
19.
go back to reference Vaclavik J, et al. Structural elucidation of novel biomarkers of known metabolic disorders based on multistage fragmentation mass spectra. J Inherit Metab Dis. 2018;41(3):407–14.PubMedCrossRef Vaclavik J, et al. Structural elucidation of novel biomarkers of known metabolic disorders based on multistage fragmentation mass spectra. J Inherit Metab Dis. 2018;41(3):407–14.PubMedCrossRef
20.
go back to reference van Vliet D, et al. Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS ONE. 2015;10(12):e0143833.PubMedPubMedCentralCrossRef van Vliet D, et al. Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS ONE. 2015;10(12):e0143833.PubMedPubMedCentralCrossRef
21.
go back to reference Wasserstein MP, et al. Cerebral glucose metabolism in adults with early treated classic phenylketonuria. Mol Genet Metab. 2006;87(3):272–7.PubMedCrossRef Wasserstein MP, et al. Cerebral glucose metabolism in adults with early treated classic phenylketonuria. Mol Genet Metab. 2006;87(3):272–7.PubMedCrossRef
22.
go back to reference Yano S, Moseley K, Azen C. Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation. J Pediatr. 2014;165(1):184–9 e1.PubMedCrossRef Yano S, Moseley K, Azen C. Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation. J Pediatr. 2014;165(1):184–9 e1.PubMedCrossRef
Metadata
Title
Patient’s thoughts and expectations about centres of expertise for PKU
Authors
A. M. J. van Wegberg
A. MacDonald
D. Abeln
T. S. Hagedorn
E. Lange
F. Trefz
D. van Vliet
F. J. van Spronsen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2021
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-020-01647-7

Other articles of this Issue 1/2021

Orphanet Journal of Rare Diseases 1/2021 Go to the issue